Digital Imaging and Afirma gene expression classifier (GEC) tests: New Diagnostics in R&D by Veracyte and GE
Reporter: Aviva Lev-Ari, PhD, RN
Veracyte will collaborate with GE Ventures, GE Healthcare, and the GE Global Research Center
Apr 14, 2015
NEW YORK (GenomeWeb) – Veracyte today announced that it has signed a research collaboration agreement with GE to develop new diagnostic approaches based on GE Healthcare’s digital imaging technology.
The partners will “explore the concept of deriving innovative diagnostic approaches from a combination of digital imaging and genomic technologies,” Veracyte CEO Bonnie Anderson said in a statement.
The firms will look to identify features from raw imaging data that, when combined with genomic information, have the potential to inform disease diagnosis.
Veracyte has amassed a large database of clinical, imaging, and genomic information from clinical trials to validate its Afirma gene expression classifier (GEC) tests, the firm said in a statement.
Under the terms of the agreement, Veracyte will collaborate with GE Ventures, GE Healthcare, and the GE Global Research Center to assess the feasibility of combining the two firms’ technologies.
Financial and other terms of the agreement were not disclosed.
Last month, Veracyte expanded a co-promotion deal for the Afirma GEC test in Brazil and Singapore with Genzyme
Related Articles
Oct 15, 2014
During Investor Day, Veracyte Outlines Growth Strategy, Future MDx Products
Premium
Aug 13, 2014
Veracyte Q2 Revenues up 71 Percent; Agrees to Amend Genyzme Deal
Mar 27, 2015
Veracyte Expands Afirma Co-promotion Deal with Genzyme to Brazil, Singapore
May 02, 2014
Fleury to Offer Veracyte Thyroid Cancer Expression Test in Brazil
Sep 03, 2014
Mixed Results for Omics, MDx Stocks in August Amid Rebound from Cool July
Dec 02, 2014
Blue Shield of California Issues Positive Coverage Policy for Veracyte’s Afirma GEC
SOURCE
Leave a Reply